The median CD34+ cell number re-transfused per transplant in myeloma patients was similar in both groups, whereas in lymphoma patients a significantly lower CD34+ cell number was re-transfused in the Plerixafor Group (p = 0.03, Table 3 and Table 4). Here, CD34 is linked to plasma cell myeloma.